Additional indications of Factive probable

Published: 2003-04-09 06:59:00

Updated: 2003-04-09 06:59:00

LG Life Sciences' Factive has received an approval letter from the US FDA as treatment against community-acquired pneumonia and acute exacerbation of chronic bronchitis, and penicillin-resistant S.pneumoniae (PRSP), excluding multi-drug resistant S.pneumoniae (MRSP).

As FDA approved the PRSP to Bayer's Avelox (moxifloxacin HCl) only for the treatment of drug-resistant pathgens, Factive's ec...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.